Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Preclinical evaluation of anticancer efficacy and pharmacological properties of FBA-TPQ, a novel synthetic makaluvamine analog.

Zhang X, Xu H, Zhang X, Voruganti S, Murugesan S, Nadkarni DH, Velu SE, Wang MH, Wang W, Zhang R.

Mar Drugs. 2012 May;10(5):1138-55. doi: 10.3390/md10051138. Epub 2012 May 23.

2.

In vitro and in vivo anticancer activity of novel synthetic makaluvamine analogues.

Wang W, Rayburn ER, Velu SE, Nadkarni DH, Murugesan S, Zhang R.

Clin Cancer Res. 2009 May 15;15(10):3511-8. doi: 10.1158/1078-0432.CCR-08-2689.

3.

Preclinical pharmacology of BA-TPQ, a novel synthetic iminoquinone anticancer agent.

Ezell SJ, Li H, Xu H, Zhang X, Gurpinar E, Zhang X, Rayburn ER, Sommers CI, Yang X, Velu SE, Wang W, Zhang R.

Mar Drugs. 2010 Jul 13;8(7):2129-41. doi: 10.3390/md8072129.

4.

A novel synthetic iminoquinone, BA-TPQ, as an anti-breast cancer agent: in vitro and in vivo activity and mechanisms of action.

Wang W, Rayburn ER, Velu SE, Chen D, Nadkarni DH, Murugesan S, Chen D, Zhang R.

Breast Cancer Res Treat. 2010 Sep;123(2):321-31. doi: 10.1007/s10549-009-0638-0. Epub 2009 Nov 21.

5.

Experimental therapy of ovarian cancer with synthetic makaluvamine analog: in vitro and in vivo anticancer activity and molecular mechanisms of action.

Chen T, Xu Y, Guo H, Liu Y, Hu P, Yang X, Li X, Ge S, Velu SE, Nadkarni DH, Wang W, Zhang R, Wang H.

PLoS One. 2011;6(6):e20729. doi: 10.1371/journal.pone.0020729. Epub 2011 Jun 6.

6.

Development and validation of an HPLC-MS/MS analytical method for quantitative analysis of TCBA-TPQ, a novel anticancer makaluvamine analog, and application in a pharmacokinetic study in rats.

Yu JX, Voruganti S, Li DD, Qin JJ, Nag S, Xu S, Velu SE, Wang W, Zhang R.

Chin J Nat Med. 2015 Jul;13(7):554-60. doi: 10.1016/S1875-5364(15)30051-0.

7.

FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer.

Wang F, Ezell SJ, Zhang Y, Wang W, Rayburn ER, Nadkarni DH, Murugesan S, Velu SE, Zhang R.

Invest New Drugs. 2010 Jun;28(3):234-41. doi: 10.1007/s10637-009-9232-x. Epub 2009 Mar 10.

PMID:
19274441
8.

Development and validation of an HPLC method for quantitation of BA-TPQ, a novel iminoquinone anticancer agent, and an initial pharmacokinetic study in mice.

Li H, Ezell SJ, Zhang X, Wang W, Xu H, Rayburn ER, Zhang X, Gurpinar E, Yang X, Sommers CI, Velu SE, Zhang R.

Biomed Chromatogr. 2011 May;25(5):628-634. doi: 10.1002/bmc.1498. Epub 2010 Sep 15.

9.

Identification of the ZAK-MKK4-JNK-TGFβ signaling pathway as a molecular target for novel synthetic iminoquinone anticancer compound BA-TPQ.

Chen D, Wang W, Qin JJ, Wang MH, Murugesan S, Nadkarni DH, Velu SE, Wang H, Zhang R.

Curr Cancer Drug Targets. 2013 Jul;13(6):651-60.

PMID:
23607596
10.

KCN1, a novel synthetic sulfonamide anticancer agent: in vitro and in vivo anti-pancreatic cancer activities and preclinical pharmacology.

Wang W, Ao L, Rayburn ER, Xu H, Zhang X, Zhang X, Nag SA, Wu X, Wang MH, Wang H, Van Meir EG, Zhang R.

PLoS One. 2012;7(9):e44883. doi: 10.1371/journal.pone.0044883. Epub 2012 Sep 13.

11.

Targeting the NF-κB and mTOR pathways with a quinoxaline urea analog that inhibits IKKβ for pancreas cancer therapy.

Radhakrishnan P, Bryant VC, Blowers EC, Rajule RN, Gautam N, Anwar MM, Mohr AM, Grandgenett PM, Bunt SK, Arnst JL, Lele SM, Alnouti Y, Hollingsworth MA, Natarajan A.

Clin Cancer Res. 2013 Apr 15;19(8):2025-35. doi: 10.1158/1078-0432.CCR-12-2909. Epub 2013 Feb 26.

12.

Lupeol inhibits proliferation and induces apoptosis of human pancreatic cancer PCNA-1 cells through AKT/ERK pathways.

Liu Y, Bi T, Wang G, Dai W, Wu G, Qian L, Gao Q, Shen G.

Naunyn Schmiedebergs Arch Pharmacol. 2015 Mar;388(3):295-304. doi: 10.1007/s00210-014-1071-4. Epub 2014 Nov 25.

PMID:
25418891
13.

Synthesis and in vitro anti-lung cancer activity of novel 1, 3, 4, 8-tetrahydropyrrolo [4, 3, 2-de]quinolin-8(1H)-one alkaloid analogs.

Nadkarni DH, Wang F, Wang W, Rayburn ER, Ezell SJ, Murugesan S, Velu SE, Zhang R.

Med Chem. 2009 May;5(3):227-36.

PMID:
19442212
14.

In vitro and in vivo anticancer efficacy of silibinin against human pancreatic cancer BxPC-3 and PANC-1 cells.

Nambiar D, Prajapati V, Agarwal R, Singh RP.

Cancer Lett. 2013 Jun 28;334(1):109-17. doi: 10.1016/j.canlet.2012.09.004. Epub 2012 Sep 26.

PMID:
23022268
15.

RL66 a second-generation curcumin analog has potent in vivo and in vitro anticancer activity in ER‑negative breast cancer models.

Yadav B, Taurin S, Larsen L, Rosengren RJ.

Int J Oncol. 2012 Nov;41(5):1723-32. doi: 10.3892/ijo.2012.1625. Epub 2012 Sep 11.

PMID:
22971638
16.

Preclinical evaluation of the novel multi-targeted agent R1530.

Kolinsky K, Tovar C, Zhang YE, Railkar A, Yang H, Carvajal D, Nevins T, Geng W, Linn M, Packman K, Liu JJ, Zhang Z, Wovkulich P, Ju G, Higgins B.

Cancer Chemother Pharmacol. 2011 Dec;68(6):1585-94. doi: 10.1007/s00280-011-1608-x. Epub 2011 May 8.

PMID:
21553286
17.

Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.

Ono N, Yamazaki T, Nakanishi Y, Fujii T, Sakata K, Tachibana Y, Suda A, Hada K, Miura T, Sato S, Saitoh R, Nakano K, Tsukuda T, Mio T, Ishii N, Kondoh O, Aoki Y.

Cancer Sci. 2012 Feb;103(2):342-9. doi: 10.1111/j.1349-7006.2011.02144.x. Epub 2011 Dec 13.

18.

Antiangiogenic versus cytotoxic therapeutic approaches to human pancreas cancer: an experimental study with a vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor and gemcitabine.

Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, Mosca F, Del Tacca M.

Eur J Pharmacol. 2004 Sep 13;498(1-3):9-18.

PMID:
15363970
19.

Antitumor effects of proteasome inhibition in anaplastic thyroid carcinoma.

Altmann A, Markert A, Askoxylakis V, Schöning T, Jesenofsky R, Eisenhut M, Haberkorn U.

J Nucl Med. 2012 Nov;53(11):1764-71. doi: 10.2967/jnumed.111.101295. Epub 2012 Oct 10.

20.

Preclinical pharmacokinetics and in vitro metabolism of brivanib (BMS-540215), a potent VEGFR2 inhibitor and its alanine ester prodrug brivanib alaninate.

Marathe PH, Kamath AV, Zhang Y, D'Arienzo C, Bhide R, Fargnoli J.

Cancer Chemother Pharmacol. 2009 Dec;65(1):55-66. doi: 10.1007/s00280-009-1002-0. Epub 2009 Apr 26.

PMID:
19396600

Supplemental Content

Support Center